Literature DB >> 21266530

Response to combined molecular targeting: defining the role of P-STAT3.

Ann Marie Egloff1, Jennifer R Grandis.   

Abstract

Src family kinase (SFK)-targeting agents are currently undergoing clinical investigation for treatment of solid malignancies. Epidermal growth factor receptor (EGFR)-independent phosphorylation of STAT3 (P-STAT3) has been identified as a mechanism of tumor resistance to agents targeting SFK. Tumor P-STAT3 levels may be an important indicator of EGFR- and SKF-targeted antitumor treatment efficacy. ©2010 AACR.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21266530      PMCID： PMC3149866          DOI： 10.1158/1078-0432.CCR-10-2925

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  11 in total

1.  Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.

Authors:  Nagathihalli S Nagaraj; M Kay Washington; Nipun B Merchant
Journal:  Clin Cancer Res       Date:  2011-01-25       Impact factor: 12.531

2.  Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.

Authors:  Nagathihalli S Nagaraj; J Joshua Smith; Frank Revetta; M Kay Washington; Nipun B Merchant
Journal:  Mol Cancer Ther       Date:  2010-08-03       Impact factor: 6.261

3.  Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.

Authors:  Eric B Haura; Tawee Tanvetyanon; Alberto Chiappori; Charles Williams; George Simon; Scott Antonia; Jhanelle Gray; Sharon Litschauer; Leticia Tetteh; Anthony Neuger; Lanxi Song; Bhupendra Rawal; Michael J Schell; Gerold Bepler
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

4.  Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.

Authors:  Faye M Johnson; B Nebiyou Bekele; Lei Feng; Ignacio Wistuba; Xi Ming Tang; Hai T Tran; Jeremy J Erasmus; Li-Ling Hwang; Naoko Takebe; George R Blumenschein; Scott M Lippman; David J Stewart
Journal:  J Clin Oncol       Date:  2010-09-20       Impact factor: 44.544

5.  Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.

Authors:  Gilda da Cunha Santos; Neesha Dhani; Dongsheng Tu; Kayu Chin; Olga Ludkovski; Suzanne Kamel-Reid; Jeremy Squire; Wendy Parulekar; Malcolm J Moore; Ming Sound Tsao
Journal:  Cancer       Date:  2010-09-07       Impact factor: 6.860

6.  A chemical and phosphoproteomic characterization of dasatinib action in lung cancer.

Authors:  Jiannong Li; Uwe Rix; Bin Fang; Yun Bai; Arthur Edwards; Jacques Colinge; Keiryn L Bennett; Jingchun Gao; Lanxi Song; Steven Eschrich; Giulio Superti-Furga; John Koomen; Eric B Haura
Journal:  Nat Chem Biol       Date:  2010-02-28       Impact factor: 15.040

7.  Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer.

Authors:  Lauren Averett Byers; Banibrata Sen; Babita Saigal; Lixia Diao; Jing Wang; Meera Nanjundan; Tina Cascone; Gordon B Mills; John V Heymach; Faye M Johnson
Journal:  Clin Cancer Res       Date:  2009-10-27       Impact factor: 12.531

8.  Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding.

Authors:  Banibrata Sen; Babita Saigal; Nila Parikh; Gary Gallick; Faye M Johnson
Journal:  Cancer Res       Date:  2009-02-17       Impact factor: 12.701

9.  Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.

Authors:  Siân Jones; Xiaosong Zhang; D Williams Parsons; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; Hirohiko Kamiyama; Antonio Jimeno; Seung-Mo Hong; Baojin Fu; Ming-Tseh Lin; Eric S Calhoun; Mihoko Kamiyama; Kimberly Walter; Tatiana Nikolskaya; Yuri Nikolsky; James Hartigan; Douglas R Smith; Manuel Hidalgo; Steven D Leach; Alison P Klein; Elizabeth M Jaffee; Michael Goggins; Anirban Maitra; Christine Iacobuzio-Donahue; James R Eshleman; Scott E Kern; Ralph H Hruban; Rachel Karchin; Nickolas Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

10.  Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors.

Authors:  Ann Marie Egloff; Jennifer Rubin Grandis
Journal:  J Oncol       Date:  2009-07-14       Impact factor: 4.375
View more
  6 in total

Review 1.  Helicobacter pylori in First Nations and recent immigrant populations in Canada.

Authors:  Nicola Jones; Naoki Chiba; Carlo Fallone; Alan Thompson; Richard Hunt; Kevan Jacobson; Karen Goodman
Journal:  Can J Gastroenterol       Date:  2012-02       Impact factor: 3.522

2.  Targeting Upstream Kinases of STAT3 in Human Medulloblastoma Cells.

Authors:  Jia Wei; Ling Ma; Chenglong Li; Christopher R Pierson; Jonathan L Finlay; Jiayuh Lin
Journal:  Curr Cancer Drug Targets       Date:  2019       Impact factor: 3.428

3.  OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer.

Authors:  V Baylot; C Andrieu; M Katsogiannou; D Taieb; S Garcia; S Giusiano; J Acunzo; J Iovanna; M Gleave; C Garrido; P Rocchi
Journal:  Cell Death Dis       Date:  2011-10-20       Impact factor: 8.469

4.  S-Nitrosoglutathione-mediated STAT3 regulation in efficacy of radiotherapy and cisplatin therapy in head and neck squamous cell carcinoma.

Authors:  Kolanjiappan Kaliyaperumal; Anand K Sharma; Daniel G McDonald; Jasdeep S Dhindsa; Caroline Yount; Avtar K Singh; Je-Seong Won; Inderjit Singh
Journal:  Redox Biol       Date:  2015-07-02       Impact factor: 11.799

5.  Elevated Src family kinase activity stabilizes E-cadherin-based junctions and collective movement of head and neck squamous cell carcinomas.

Authors:  Laurence Veracini; Dominique Grall; Sébastien Schaub; Stéphanie Beghelli-de la Forest Divonne; Marie-Christine Etienne-Grimaldi; Gérard Milano; Alexandre Bozec; Emmanuel Babin; Anne Sudaka; Juliette Thariat; Ellen Van Obberghen-Schilling
Journal:  Oncotarget       Date:  2015-04-10

6.  Interleukin-6 and Interleukin-8 Regulate STAT3 Activation Migration/Invasion and EMT in Chrysophanol-Treated Oral Cancer Cell Lines.

Authors:  Po-Chih Hsu; Yi-Hsuan Chen; Ching-Feng Cheng; Chan-Yen Kuo; Huey-Kang Sytwu
Journal:  Life (Basel)       Date:  2021-05-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.